Vestal Point Capital, LP Apellis Pharmaceuticals, Inc. Call Options Transaction History
Vestal Point Capital, LP
- $1.69 Trillion
- Q4 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding APLS
# of Institutions
302Shares Held
123MCall Options Held
2.63MPut Options Held
845K-
Avoro Capital Advisors LLC New York, NY12.2MShares$301 Million5.68% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$293 Million17.73% of portfolio
-
Wellington Management Group LLP Boston, MA11.8MShares$291 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$248 Million0.01% of portfolio
-
Morgan Stanley New York, NY9.63MShares$237 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.71B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...